TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review

Yoshikuni Nagayama, Mizuki Yamano, Motoka Yagame, Tomoyuki Nariyama, Mikiko Takahashi, Masashi Kawamoto and Katsuyuki Matsui

Abstract

Background: TAFRO syndrome is a systemic inflammatory disorder that manifests as thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly (O). Renal dysfunction is frequently complicated with TAFRO syndrome, however, it is challenging to perform kidney biopsy in patients with TAFRO syndrome in the presence of thrombocytopenia. Renal histology in TAFRO syndrome mainly shows membranoproliferative glomerulonephritis (MPGN)-like lesions or thrombotic microangiopathy (TMA)-like glomerulopathy. We review our case and previous reports of TAFRO syndrome with kidney biopsy findings and discuss the renal pathophysiology of TAFRO syndrome.

Case presentation: We describe a previously healthy 48-year-old woman with TAFRO syndrome. Kidney biopsy performed before the treatment showed diffuse global endocapillary proliferative changes with endothelial cell swelling, double contours of partial capillary walls, and mesangiolysis, consistent with TMA-like glomerulopathy. Glucocorticoid therapy including steroid pulse was ineffective and she developed anasarca, renal dysfunction and oliguria. Hemodialysis was required. However, the anti-Interleukin (IL)-6 receptor antibody (tocilizumab) therapy was very effective. An increase in urinary volume was achieved about 2 weeks after the tocilizumab therapy and hemodialysis was discontinued. To investigate the renal pathophysiology of TAFRO syndrome, we performed immunohistological staining of vascular endothelial growth factor (VEGF)-A, CD34, and D2–40, in our case and a normal control kidney. Glomerular VEGF-A was especially positive in podocytes both, in the control and in the case, with no significant difference and there was a significant increase of VEGF-A staining area in the cortical peritubular capillaries in the case. Both glomerular and renal cortical CD34 expression were significantly decreased in our case. D2–40 expression in cortex was not significantly different.

Conclusions: We reviewed our case and other 10 previous reports about renal biopsy findings in TAFRO syndrome and found that glomerular microangiopathy was a common finding. IL-6-VEGF-axis-induced glomerular microangiopathy may play a crucial role in developing acute kidney injury in TAFRO syndrome and the anti-IL-6 receptor antibody therapy may be useful for TAFRO syndrome refractory to glucocorticoids. About the pathophysiology of VEGF in TAFRO syndrome, VEGF balance in the glomerulus and perhaps in the peritubular capillary system as well may be critical. Further investigation is needed.

Keywords: Castleman disease, Interleukin (IL)-6, Membranoproliferative glomerulonephritis (MPGN), TAFRO syndrome, Thrombotic microangiopathy (TMA), Tocilizumab, Vascular endothelial growth factor (VEGF)
Background
TAFRO syndrome is a systemic inflammatory disorder that manifests as thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly (O) [1]. In 2015, the Japanese diagnostic criteria and treatment strategy of TAFRO syndrome were published [2]. A diagnosis of TAFRO syndrome requires the fulfillment of all three major criteria and at least two of the four minor criteria as follows: The major criteria include (1) Anasarca, including pleural effusion, ascites, and general edema, (2) Thrombocytopenia defined as pre-treatment platelet count \( \leq 100 \times 10^3/\mu L \), and (3) Systemic inflammation defined as fever of unknown etiology (body temperature > 37.5 °C and/or serum C-reactive protein (CRP) concentration \( \geq 2 \text{ mg/dL} \)). The minor criteria include (1) Castleman disease-like features on lymph node biopsy, (2) Reticulin myelofibrosis and/or increased number of megakaryocytes in the bone marrow, (3) Mild organomegaly, including hepatomegaly, splenomegaly and lymphadenopathy, and (4) Progressive renal insufficiency. Malignancies; autoimmune disorders; infectious disorders; polynuropathy, organomegaly, endocrinopathy, M-protein, skin change syndrome; immunoglobulin G4 (IgG4)-related disease; hepatic cirrhosis; and thrombotic thrombocytopenic purpura (TTP) /hemolytic uremic syndrome must be excluded. Recently, TAFRO syndrome was proposed as a distinct subtype of human herpes virus (HHV)-8-negative multicentric Castleman disease [3]. Renal dysfunction is frequently complicated with TAFRO syndrome. In the presence of thrombocytopenia, it is challenging to perform kidney biopsy in patients with TAFRO syndrome. However, kidney biopsy is being performed for an increasing number of TAFRO syndrome patients. Renal histology in TAFRO syndrome mainly shows membranoproliferative glomerulonephritis (MPGN)-like lesions or thrombotic microangiopathy (TMA)-like glomerulopathy [4–13]. We report a case of TAFRO syndrome with TMA-like glomerulopathy that was successfully treated with an anti-interleukin (IL)-6 receptor antibody (tocilizumab) and discuss the renal pathophysiology of TAFRO syndrome.

Case presentation
Clinical history and initial laboratory data
A previously healthy 48-year-old woman underwent a medical check at our hospital for whole body edema (face, extremities, and abdomen). A few weeks previously, she had experienced headache and fever. Laboratory findings showed proteinuria (1.57 g/g creatinine using spot urine), renal dysfunction (serum creatinine 1.08 mg/dL), and higher CRP level (16.7 mg/dL). A plain computed tomography revealed multiple lymphadenopathy. She was admitted to our hospital for further investigation. Her clinical findings on admission were as follows: blood pressure, 148/92 mmHg; pulse rate, 100/ min; body temperature, 39.3 °C; height, 156 cm; and weight, 74 kg. She was alert and had mild facial, upper and lower-extremity, and abdominal edema. She reported slight upper-abdominal pain. She had no superficial lymphadenopathy, joint pain, neurological findings, or skin lesions, and an examination of her heart and lungs was unremarkable. Laboratory findings on admission are shown in Table 1. Urinalysis showed proteinuria (protein 3+ and blood ± by dipstick, and some ovary fatty bodies), and the blood tests revealed hyperleukocytosis (77.6% neutrophils, 11.1% lymphocytes, 10.8% monocytes), abnormal coagulation, hypoproteinemia, renal dysfunction [serum creatinine, 1.32 mg/dl; estimated glomerular filtration rate (eGFR), 34.84 ml/min/1.73 m²], elevated alkaline phosphatase, elevated γ-glutamyl transpeptidase, and elevated CRP. eGFR was calculated by using the Japanese eGFR equation (eGFR = 194 × serum creatinine \(-1.094 \times \text{Age}^{-0.287} \times 0.739 \) [14]. The patient did not have hypergammaglobulinemia or hypocomplementemia, and soluble IL-2 receptor was elevated. The patient showed negative for various autoantibodies, hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), HHV-8, and tuberculosis infections. IL-6 and vascular endothelial growth factor (VEGF) were remarkably elevated. ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13) activity was decreased to 0.633 IU/mL, which was not low enough to be shown in typical TTP.

Kidney biopsy findings
Kidney biopsy was performed at the 6th hospital day before the treatment.

Light microscopy
There were 25 glomeruli present in 2 cores, of which 1 glomerulus was globally sclerosed. In periodic-acid Schiff staining, glomeruli showed diffuse global endocapillary proliferative changes with endothelial swelling and some infiltration of macrophages (Fig. 1a). Periodic acid-silver-methenamine staining revealed double contours of partial capillary walls and mesangiolysis (Fig. 1b). There was no hyalinosis, segmental sclerosis, or fibrin thrombi. Bowman’s space had no adhesions, fibrin, or crescents. The interstitium showed few focal cell infiltrates, and there was mild tubular atrophy and interstitial fibrosis. Arteries showed mild sclerosis of the intima.

Immunofluorescence microscopy
Immunofluorescence was negative for IgG, IgA, IgM, C1q, C3c, C4, κ, λ, and fibrinogen.
Electron microscopy (Fig. 1c)
There was marked edema in the subendothelial space and in the mesangial area. There were no electron dense deposits. Epithelial cells showed partial foot process effacement and microvillous transformation.

VEGF-A, CD34, and D2–40 staining
An additional file shows the immunodetection and statistical methods (see Additional file 1). We performed immunohistological staining of VEGF-A, CD34, a marker of endothelium, and D2–40, a marker of lymphatic vessels in our case and a normal control kidney (a normal portion of a resected kidney in a patient with renal cell carcinoma) and quantitatively analyzed it (Table 2). Glomerular VEGF-A was especially positive in podocytes both, in the control (Fig. 2a) and in the case (Fig. 2b), with no significant difference in the VEGF-A positive staining area in glomeruli (%) between the control and the case (1.6 ± 0.40 vs. 2.0 ± 0.55, respectively, \( P = 0.63 \)). However, VEGF-A positive staining area in the renal cortex (%) was significantly increased in our case (Fig. 2h) than in the control (Fig. 2g) (1.6 ± 0.31 vs. 0.32 ± 0.072, respectively, \( P < 0.0001 \)). CD34 was positive in glomerular and peritubular capillaries, and arterioles both, in the control (Fig. 2c and i) and in the case (Fig. 2d and j). Glomerular CD34

| Table 1 Laboratory findings on admission |
| Parameter | Value (reference range) | Parameter | Value (reference range) |
|-----------|-------------------------|-----------|-------------------------|
| Hematology |                         | Urine BJP | negative                |
| WBC count, /μL | 10,160 (3500–9100) | Immunology |                         |
| Hemoglobin, g/dL | 12.6 (11.3–15.2) | IgG, mg/dL | 842 (820–1740)          |
| Platelet count, 10^4/μL | 20.5 (13.0–36.9) | IgG4, mg/dL | 28 (5–117)           |
| PT, % | 65.5 (80–100) | IgA, mg/dL | 166 (90–400)          |
| APTT, seconds | 40.7 (24–39) | IgM, mg/dL | 100 (52–270)         |
| FDP, μg/mL | 26 (< 5) | IgE, IU/mL | 23 (< 170)            |
| Blood chemistry |                   | C3, mg/mL | 1.62 (0.86–1.6)       |
| Cr, mg/dL | 1.32 (0.46–0.79) | C4, mg/mL | 0.35 (0.17–0.45)      |
| eGFR, mL/min/1.73m² | 34.84 | ANA | negative                |
| SUN, mg/dL | 21 (9–20) | MPO-ANCA | negative                |
| Total protein, g/dL | 5.9 (6.7–8.3) | PR3-ANCA | negative                |
| Albumin, g/dL | 2.6 (3.8–5.1) | Anti-GBM antibody | negative                |
| AST, U/L | 19 (10–40) | Anti-SS-a/b antibody | negative                |
| ALT, U/L | 9 (5–45) | RF | negative                |
| LDH, U/L | 229 (120–240) | Cryoglobulin | negative                |
| ALP, U/L | 1845 (104–338) | sIgL-2R, U/mL | 986 (122–496)         |
| γ-GTP, U/L | 569 (0–42) | Anti-CL IgG | negative                |
| T-Chol, mg/dL | 156 (150–219) | Anti-CLβ2GPI complex | negative                |
| TG, mg/dL | 159 (50–150) | ADAMTS13 activity, IU/mL | 0.633 (0.780–1.570) |
| Glucose, mg/dL | 124 (75–110) | IL-6, pg/mL | 166 (< 8)             |
| HbA1c | 6.1 (4.6–6.2) | VEGF, pg/mL | 494 (< 38.3)         |
| CRP, mg/dL | 18.33 (0–0.29) | HBV surface antigen | negative                |
| Urinalysis |                   | HCV antibody | negative                |
| Urine dipstick protein | 3+ | HIV antibody | negative                |
| Urine occult blood ± |       | HHV-8 DNA | negative                |
| Spot Urine PCR, g/g | 1.57 | T-SPOT assay | negative                |

Abbreviations: ADAMTS13 A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13, ALP Alkaline phosphatase, ALT Alanine aminotransferase, ANA Antinuclear antibody, ANCA Antineutrophil cytoplasmic antibody, APTT Activated partial thromboplastin time, AST Aspartate aminotransferase, BJP Bence Jones protein, CL Cardiolipin, Cr creatinine, CRP C-reactive protein, DNA Deoxyribonucleic acid, eGFR estimated glomerular filtration rate, FDP Fibrin degradation products, GBM Glomerular basement membrane, GTP Glutamyl transpeptidase, HbA1c Hemoglobin A1c, HBV Hepatitis B virus, HCV Hepatitis C virus, HIV Human immunodeficiency virus, IgA Immunoglobulin A, IgG Immunoglobulin G, IgG4 Immunoglobulin G4, IgM Immunoglobulin M, IL Interleukin, LDH Lactate dehydrogenase, MPO Myeloperoxidase, PCR Protein-creatinine ratio, PR3 Proteinase 3, PT Prothrombin time, RF Rheumatoid factor, sIgL-2R Soluble interleukin-2 receptor, SS Sjoegren syndrome, SUN Serum urea nitrogen, T-Chol Total cholesterol, TG Triglyceride, VEGF Vascular endothelial growth factor, WBC White blood cell
positive staining area (%) was significantly decreased in our case (Fig. 2d) compared to the control (Fig. 2c) (5.4 ± 0.48 vs. 22 ± 1.2, respectively, \( P < 0.0001 \)). CD34 positive staining area in the renal cortex (%) was also significantly decreased in our case (Fig. 2j) compared to the control (Fig. 2i) (2.5 ± 0.23 vs. 7.1 ± 0.29, respectively, \( P < 0.0001 \)). D2–40 was negative in the glomerulus both in the control (Fig. 2e) and in the case (Fig. 2f), and D2–40 was also negative in the targeted cortex area both in the control (Fig. 2k) and in the case (Fig. 2l). In a small part of renal cortex, D2–40 was positive both in the lymphatic vessels of the control (Additional file 2: Figure S1A) and in the case (Additional file 2: Figure S1B), with no significant difference in the D2–40 positive staining area (%) between the control and the case (0.22 ± 0.091 vs. 0.072 ± 0.030, respectively, \( P = 0.39 \)). Each Fig. 2a, c, or e shows a same glomerulus in the control and each Fig. 2b, d, or f shows a same glomerulus in our case. Each Fig. 2g, i, or k shows a same cortical interstitium area in the control and each Fig. 2h, j, or l shows a same cortical interstitium area in the case. In the cortical interstitium of the case, VEGF-A was mainly positive in the peritubular capillaries but not in the lymphatic vessels.

Clinical course
The clinical course is illustrated in Fig. 3. Anasarca, including pleural effusion, ascites, and general edema gradually deteriorated. Biopsy of the porta hepatis lymph node with endoscopic ultrasound-fine needle aspiration (EUS-FNA) was performed at the 11th hospital day before the treatment. There was no evidence of Castleman disease or malignant lymphoma. Just before treatment initiation, her platelet count was < 100 × 10^3/μL. Based on the criteria [2], her clinical and laboratory findings fulfilled the diagnostic criteria for TAFRO syndrome. A bone marrow biopsy revealed a normocellular marrow with increased number of megakaryocytes, without myelofibrosis. Steroid pulse therapy (500 mg/day of intravenous methylprednisolone) was initiated for 3 days from the 11th hospital day. Thereafter, 40 mg/day of prednisolone was administered orally. However, she developed anasarca, renal dysfunction, and oliguria. Hemodialysis was required from the 15th hospital day. Moreover, serum CRP level remained high, and she experienced considerable painful; therefore, treatment with an anti-IL-6 receptor antibody (tocilizumab) was started at a

| Table 2 Immunohistological analysis in the control and in the case |
|-------------------------------|-------------------------------|---------------------|
| VEGF-A positive area in glomeruli (%) | 1.6 ± 0.40 | 2.0 ± 0.55 | 0.63 |
| VEGF-A positive area in cortex (%) | 0.32 ± 0.072 | 1.6 ± 0.31 | < 0.0001 |
| CD34 positive area in glomeruli (%) | 22 ± 1.2 | 5.4 ± 0.48 | < 0.0001 |
| CD34 positive area in cortex (%) | 7.1 ± 0.29 | 2.5 ± 0.23 | < 0.0001 |
| D2–40 positive area in cortex (%) | 0.22 ± 0.091 | 0.072 ± 0.030 | 0.39 |
Fig. 2 VEGF-A, CD34, and D2–40 staining in kidney biopsy. Glomerular VEGF-A was mainly positive in podocytes both, in the control (a) and in the case (b) with no significant difference. Cortical VEGF-A positive staining area was significantly increased in our case (h) than in the control (g). CD34, a marker of endothelium, was positive in glomerular and peritubular capillaries, and arterioles both, in the control (c and i) and in the case (d and j). Both glomerular and cortical CD34 positive staining area were significantly decreased in our case compared to the control. D2–40, a marker of lymphatic vessels, was negative in the glomerulus both in the control (e) and in the case (f). In addition, D2–40 was negative in the targeted cortex area both in the control (k) and in the case (l). Each Fig. 2a, c, or e shows a same glomerulus in the control and each figure (b), (d), or (f) shows a same glomerulus in our case. Each Fig. 2g, i, or k shows a same cortical interstitium area in the control and each Fig. 2h, j, or l shows a same cortical interstitium area in the case. In the cortical interstitium of the case, VEGF-A was mainly positive in the peritubular capillaries but not in the lymphatic vessels. (Original magnification,× 1000)

Fig. 3 Clinical course of the patient. After the diagnosis of TAFRO syndrome, steroid pulse therapy (500 mg/day of intravenous methylprednisolone) was initiated for 3 days from the 11th hospital day. Thereafter, 40 mg/day of prednisolone was administered orally. However, she developed anasarca, renal dysfunction, and oliguria. Hemodialysis was required from the 15th hospital day. Moreover, serum CRP level remained high, and she experienced considerable pain; therefore, treatment with an anti-IL-6 receptor antibody (tocilizumab) was started at a dose of 8 mg/kg (400 mg/day). Her pain reduced considerably; there was gradual improvement in her condition with respect to renal function and edema. Tocilizumab was administered again after 2 weeks. There was an increase in the urinary volume about 2 weeks after the tocilizumab therapy, and hemodialysis was discontinued. Serum VEGF and IL-6 levels after the second tocilizumab therapy were lower at 39.6 pg/mL (normal < 38.3) and 110 pg/mL (normal < 8), respectively. After the dose of prednisolone was tapered to 35 mg/day, 150 mg/day of cyclosporine was administered orally. However, oral cyclosporine was stopped because of adverse effects such as liver dysfunction and vomiting. She was discharged on hospital day 58. Abbreviations: BW: body weight; Cre: Creatinine; CRP: C-reactive protein; CyA: cyclosporine; IL: Interleukin; m-PSL: methylprednisolone; Plt: platelets; PSL: Prednisolone; TCZ: tocilizumab; VEGF: Vascular endothelial growth factor.
dose of 8 mg/kg (400 mg/day). Her pain reduced considerably; there was gradual improvement in her condition with respect to renal function and edema. Tocilizumab was administered again after 2 weeks. There was an increase in the urinary volume about 2 weeks after the tocilizumab therapy, and hemodialysis was discontinued. Serum VEGF and IL-6 levels after the second tocilizumab therapy were lower at 39.6 pg/mL and 110 pg/mL, respectively. After the dose of prednisolone was tapered to 35 mg/day, 150 mg/day of cyclosporine was administered orally. However, oral cyclosporine was stopped because of adverse effects such as liver dysfunction and vomiting. She was discharged on hospital day 58. About 1 year after discharge, prednisolone had been tapered to 5 mg/day, and her renal outcome was stable (final serum creatinine level was 0.70 mg/dL and urinary protein was negative).

**Discussion and conclusions**

Several studies have examined renal biopsy findings in TAFRO syndrome (Table 3) [4–13]. Renal histology in the 10 patients [4–13] and our patient mainly showed MPGN-like lesions or TMA-like glomerulopathy. The timing of the kidney biopsy performed in these patients varied from the acute phase [8–13] to the chronic phase [4–7]; however, glomerular microangiopathy was a common finding. We explored the details of kidney biopsy findings in the literature review and found that 3 (Case no.3 and 5–6, Table 3) out of 5 cases diagnosed as MPGN-like glomerulopathy had no glomerular immune deposits. We could diagnose these three cases as TMA-like glomerulopathy. If so, all patients with kidney biopsy performed in the acute phase (Case no. 5–10, Table 3 and our case) could be diagnosed as TMA-like glomerulopathy. On the other hand, in four patients with kidney biopsy performed in the chronic phase (Case no. 1–4, Table 3), two patients (Case no.1 and 2, Table 3) were diagnosed as MPGN-like glomerulopathy and the others (Case no.3 and 4, Table 3) could be diagnosed as TMA-like glomerulopathy. In TAFRO syndrome, we suspect that TMA appears in acute phase and the renal histology shows MPGN in chronic phase. In the 11 cases of TAFRO syndrome with kidney biopsy, there was no clear evidence of systemic microangiopathy including hemolytic anemia or organ dysfunction except kidney. Local glomerular microangiopathy was characteristic of these patients with TAFRO syndrome.

Serum VEGF and IL-6 levels are usually elevated in TAFRO syndrome and are considered pathogenic factors. In our case, serum VEGF and IL-6 levels were decreased, as patient condition improved. In Table 3, all cases except Case no. 4 presented with elevated serum IL-6 and/or VEGF. Therefore, IL-6-induced VEGF overproduction may lead to glomerular endothelial injury [15]. Striking glomerular endothelial injury can rapidly reduce glomerular filtration rates, causing oliguric kidney injury. IL-6-VEGF-axis-induced glomerular microangiopathy may play a crucial role in developing acute kidney injury in TAFRO syndrome. In contrary, VEGF may protect renal TMA. Systemic administration of VEGF accelerated the renal recovery in a rat TMA model [16, 17]. However, systemic inhibition of VEGF signaling with anti-VEGF therapy in six patients caused TMA-like glomerulopathy with endothelial injury, and a mouse model of podocyte-specific VEGF deletion developed TMA-like glomerular lesions [18]. Whether VEGF plays a causative or protective role or both in renal TMA remains unclear and further studies are needed. Moreover, the site of VEGF (systemic or local) that plays an important role in glomerular microangiopathy remains unclear. A podocyte-specific VEGF transgenic mouse showed proteinuria and focal effacement of the podocytes without defects in glomerular endothelial cells on transmission electron microscopy [19]. VEGF-VEGF receptor paracrine signaling between podocytes and glomerular endothelial cells is considered essential for the maintenance of glomerular endothelial cells [19]. Decrease in the glomerular VEGF levels may cause failure of homeostasis in the endothelium and lead to the development of TMA. Either too much or too little VEGF in the glomerulus may lead to glomerular pathology.

TMA-like glomerulopathy was the most common feature of renal involvements in Castleman disease [20]. There were no significant differences in the glomerular VEGF expression among patients with TMA with or without Castleman disease and healthy controls [20]. In some patients with a type of Castleman disease-associated TMA (small-vessel lesion group), glomerular VEGF expression was decreased [20]. However, limited information is available about glomerular VEGF expression in TAFRO syndrome. Glomerular VEGF staining in TAFRO syndrome has been reported only in two cases [10, 11]. One was VEGF negative and the other was VEGF positive. We performed immunohistological staining of VEGF-A, CD34, and D2–40, in our case and a normal control kidney, and quantitatively analyzed it. Glomerular VEGF-A was especially positive in podocytes both, in the control and in the case, with no significant difference, although significant difference of glomerular VEGF-A expression between the control and the case was expected. It is noteworthy that the VEGF-A positive staining area in the renal cortex was significantly increased in our case than in the control. Both glomerular and renal cortical CD34 positive staining area were significantly decreased in our case compared to the control. It is reported that glomerular capillary injuries in acute and chronic glomerular lesions in patients with IgA nephropathy were associated with the loss of CD34.
Table 3 Clinical characteristics of 11 cases of TAFRO syndrome with kidney biopsy

| Case no./Ref. | Age/sex | UP Alb (g/dL) | Cr (mg/dL) | CRP (mg/dL) | VEGF/IL-6 (pg/mL) | 1st Therapy/response | 2nd Therapy/response | Kidney biopsy findings | Thrombi | Endothelial swelling | Endocapillary proliferation | Mesangiolysis | Mesangial proliferation | Double contours of GBM | Glomerular Ig deposition by IF | Subendothelial lesions by EM | Electron dense deposits | Diagnosis by authors |
|--------------|---------|---------------|------------|-------------|------------------|----------------------|----------------------|-----------------------|---------|---------------------|---------------------------|---------------|----------------------|----------------|--------------------------|------------------------|------------------------|-------------------|
| 1/ [4]       | 38 / M  | n.d.          | 2.59       | 11.18       | 4420 / n.d.      | PSL / good          | n.d. n.d. n.d. n.d. | Yes       | Yes     | Yes               | Yes                     | Yes          | Yes                  | No            | n.d.                     | n.d.                   | MPGN-like             |
| 2/ [5]       | 55 / F  | 0.54 (g/g Cr) | 2.7        | 2.1         | 464 / 11.7       | Pulse steroid / good| n.d. n.d. n.d. n.d. | Yes       | Yes     | No                | Yes                     | No           | Yes                  | No            | n.d.                     | TMA-like               | MPGN-like             |
| 3/ [6]       | 76 / F  | 0.30 (g/day)  | 1.2        | 3.02        | 1350 / 49.2      | PSL / good          | n.d. n.d. Yes n.d.  | Yes       | Yes     | No                | Yes                     | Yes          | No                   | No            | n.d.                     | n.d.                   | MPGN-like             |
| 4/ [7]       | 79 / F  | 2.65 (g/g Cr) | 2.4        | 3.3         | 156 / 3.76       | Pulse, PE / bad     | RTX n.d. n.d. No    | Yes       | No      | Yes               | Yes                     | Yes          | Yes                  | Yes           | n.d.                     | TMA-like               |
| 5/ [8]       | 70 / M  | 0.33 (g/day)  | 2.5        | 12.8        | 126 / 33         | Pulse steroid / good| - No Yes No Yes  | No       | Yes     | Yes               | Yes                     | Yes          | Yes                  | Yes           | No                      | No                     | MPGN-like             |
| 6/ [9]       | 61 / F  | n.d.          | 2.8        | 2.14        | 23.12            | Pulse steroid, TCZ, RTX / good | n.d. Yes n.d. Yes | Yes       | Yes     | Yes               | Yes                     | Yes          | Yes                  | Yes           | n.d.                     | n.d.                   | MPGN-like             |
| 7/ [10]      | 80 / F  | 0.41 (g/day)  | 2.8        | 1.17        | 454 / 21.6       | PSL /bad TCZ / good | No Yes Yes No No  | Yes       | Yes     | No                | Yes                     | Yes          | Yes                  | Yes           | No                      | TMA-like               |
| 8/ [11]      | 51 / F  | 0.52 (g/g Cr) | 2.5        | 1.03        | 198 / 21.2       | Pulse steroid / good| - n.d. Yes No Yes  | No       | Yes     | No                | Yes                     | Yes          | Yes                  | Yes           | n.d.                     | TMA-like               |
| 9/ [12]      | 84 / M  | 0.30 (g/day)  | 2.4        | 2.31        | 177 / 12.3       | PSL, PE /bad TCZ / good | No Yes Yes Yes No  | No       | Yes     | Yes               | Yes                     | Yes          | No                   | No            | TMA-like                 |
| 10/ [13]     | 54 / F  | 3.2 (g/g Cr)  | 2.4        | 1.11        | 98 / 8.2         | PSL / good          | - No Yes No No   | No       | Yes     | No                | Yes                     | Yes          | No                   | Yes           | No                      | Endothelial injury    |
| our case     | 48 / F  | 1.57 (g/g Cr) | 2.6        | 1.32        | 18.33            | Pulse steroid /bad  | TCZ / good Yes Yes | Yes       | Yes     | Yes               | Yes                     | Yes          | No                   | No            | Yes                     | TMA-like               |

Abbreviations: Alb Albumin; Cr Creatinine, CRP C-reactive protein, EM Electron microscopy, GBM Glomerular basement membrane, IF Immunofluorescence, Ig Immunoglobulin, IL Interleukin, MPGN Membranoproliferative glomerulonephritis, n.d. not data, PE Plasma exchange, PSL Prednisolone, RTX rituximab, TCZ tocilizumab, TMA Thrombotic microangiopathy, UP Urinary protein, VEGF Vascular endothelial growth factor
positive glomerular endothelial cells [21], however, the association between TMA and CD34 staining remains unknown. The weakness of CD 34 staining in our case may reflect microangiopathy. In a small part of renal cortex, D2–40 was positive both in the control and in the case with no significant difference. As a result of additional CD34 and D2–40 staining, VEGF-A was mainly positive in the peritubular capillaries, but not in the lymph ducts in the cortical interstitium. VEGF homeostasis that the exact balance of VEGF in the glomerulus and perhaps in the peritubular capillary system as well may be critical. Unfortunately, we were not able to evaluate any differences in peritubular capillary ultrastructure that could help explain pathophysiology. Further studies about renal VEGF expression in TAFRO syndrome are warranted.

By the Japanese diagnostic criteria and treatment strategy of TAFRO syndrome (2015 version) [2], first line therapy for TAFRO syndrome is high-dose glucocorticoid. For TAFRO syndrome refractory to or dependent on glucocorticoids, immunosuppressants including cyclosporine, tocilizumab, and rituximab are considered. In our case, the glucocorticoid therapy, including steroid pulse was ineffective; however, the anti-IL-6 receptor antibody (tocilizumab) therapy was very effective. It is suggested that IL-6-VEGF axis contributed to systemic inflammation and increased vascular permeability in our case. Table 3 shows that glucocorticoid therapy was effective in 6 out of 11 patients with TAFRO syndrome with biopsy-proven MPGN-like or TMA-like glomerulopathy and tocilizumab therapy was effective in 3 out of 4 of the patients resistant to steroids. Tocilizumab therapy may be a useful choice in patients with TAFRO syndrome with MPGN-like or TMA-like glomerulopathy.

In conclusion, we reported a case of TAFRO syndrome with TMA-like glomerulopathy with successful treatment by tocilizumab. We reviewed our case and other 10 previous reports about renal biopsy findings in TAFRO syndrome and found that glomerular microangiopathy was a common finding. IL-6-VEGF-axis-induced glomerular microangiopathy may play a crucial role in developing acute kidney injury in TAFRO syndrome. The anti-IL-6 receptor antibody therapy may be useful for TAFRO syndrome refractory to glucocorticoids. Glomerular VEGF-A was especially positive in podocytes both, in the control and in the case, with no significant difference. However, the VEGF-A positive staining area in the cortical peritubular capillaries was significantly increased in our case than in the control. VEGF homeostasis that the exact balance of VEGF in the glomerulus and perhaps in the peritubular capillary system as well may be critical. Further investigation about the pathophysiology of VEGF in TAFRO syndrome is needed.

### Supplementary information

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12882-019-1574-9.

**Additional file 1.** Immunodetection and Statistical Methods.

**Additional file 2: Figure S1.** In a small part of renal cortex, D2–40 was positive both in the lymphatic vessels of the control (A) and in the case (B).

**Abbreviations**

ADAMTS13: A disintegrin and metalloprotease with thrombospondin type 1 motifs 13; CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; EUS-FNA: Endoscopic ultrasound-fine needle aspiration; HHV: Human herpes virus; HIV: Human immunodeficiency virus; IgG4: Immunoglobulin G4; IL: Interleukin; MPGN: Membranoproliferative glomerulonephritis; TMA: Thrombotic microangiopathy; TTP: Thrombotic thrombocytopenic purpura; VEGF: Vascular endothelial growth factor

**Acknowledgments**

The authors thank Kazutoshi Unno, Masahito Yamada, and Kazuhiro Yuzawa for their technical assistances, as well as Dr. Kersuke Joh (Department of Pathology, The Jikei University School of Medicine) for suggestions concerning the pathologic evaluation.

**Authors’ contributions**

YN, MY2, TN, and KM performed medical care of the patient. YN conceived and designed the study. YN acquired, analyzed and interpreted data. YN drafted the manuscript. YN, MY1, MT, MK, and KM diagnosed kidney pathology. YN, MY1, MT, MK, and KM critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript. MY1 and MY2 are corresponding to Mizuji Yamano and Motoka Yagame, respectively.

**Funding**

This study was not supported any funding.

**Availability of data and materials**

Further clinical data and images of this case are available from the corresponding author upon reasonable request.

**Ethics approval and consent to participate**

Not applicable for this case report.

**Consent for publication**

Written informed consent was obtained from the patient for publication of this case report.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Internal Medicine IV, Teikyo University School of medicine, University Hospital, Mizonokuchi, Kawasaki, Japan. 2. Department of Diagnostic Pathology, Teikyo University School of Medicine, University Hospital, Mizonokuchi, Kawasaki, Japan.

**Received:** 12 April 2019  **Accepted:** 30 September 2019  **Published online:** 17 October 2019

**References**

1. Kawabata H, Takai K, Kojima M, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June,2012) and Nagoya (meetings 22 September,2012). J Clin Exp Hematol. 2013;53(1):157–61 doi: 10.3960/jjom.2013.53.57.

2. Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016;103(6):686–92. https://doi.org/10.1007/s12185-016-1979-1.
3. Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91(2):220–6. https://doi.org/10.1002/ajh.24242.

4. Kawashima M, Usui T, Okada H, et al. TAFRO syndrome: 2 cases and review of the literature. Mod Rheumatol. 2017;27(6):1093–7. https://doi.org/10.1002/1439-7595.2015.1059982.

5. Furuto Y, Hashimoto H, Horii H, Shiibuya Y. Membranoproliferative glomerulonephritis-like findings for TAFRO syndrome, associated with an anterior mediastinal tumor: A case report. Medicine (Baltimore). 2018;97(24): e11057 doi: 10.1097/MD.00000000000011057.

6. Ito S, Uchida T, Itai H, et al. Serial manifestation of acute kidney injury and nephrotic syndrome in a patient with TAFRO syndrome. Intern Med. 2018;57(21):3129–33. https://doi.org/10.2169/internalmedicine.0806-18.

7. Noda Y, Saka Y, Kato A, Minuma T, Naruse T. Successful rituximab treatment of TAFRO syndrome with pathological findings of glomerular endothelial damage. Clin Nephrol Case Stud. 2018;6(1):16–20 doi: 10.5414%2FCNCS109400.

8. Tanaka M, Tsujimoto H, Yamamoto K, Shimoda S, Oka K, Takeoka H. Clinicopathological features of progressive renal involvement in TAFRO syndrome: a case report and literature review. Medicine (Baltimore). 2017;96(7):1 162–92. https://doi.org/10.1097%2FMD.0000000000008216.

9. Jose FF, Kerbauy LN, Perini GF, et al. A life-threatening case of TAFRO syndrome with diastolic response to tocilizumab, rituximab, and pulse steroids: the first case report in Latin America. Medicine (Baltimore). 2017;96(13):e1271 doi: 10.1097%2FMD.0000000000006271.

10. Noda-Narita S, Sumida K, Sekine A, et al. TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report. CEN Case Rep. 2018;7(1):162–8. doi: 10.1007%2Fs13730-018-0319-0.

11. Ozeki T, Tsuji M, Yamamoto K, Shigematsu C, Maruyama S. Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome. CEN Case Rep. 2018;7(2):243–7. https://doi.org/10.1007%2Fs13730-018-0338-x.

12. Mizuno H, Sekine A, Oguro M, et al. Renal histology in a patient with TAFRO syndrome: a case report. Hum Pathol. 2018;57(8):1123–9 doi: 10.2169%2Finternalmedicine.9556-17.

13. Nakamori A, Akagaki F, Yamaguchi Y, Arima R, Sugiuura T. Nephrotic syndrome with thrombocytopenia, lymphadenopathy, systemic inflammation, and splenomegaly. Intern Med. 2018;57(8):1123–9 doi: 10.2169%2Finternalmedicine.9556-17.

14. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92. https://doi.org/10.1053/j.ajkd.2008.12.034.

15. Seida A, Wada J, Morita Y, et al. Multicentric Castleman’s disease associated with glomerular microangiopathy and MPGN-like lesions: does vascular endothelial cell-derived growth factor play causative or protective roles in injury? Am J Kidney Dis. 2004;44(1):1 129–36 doi: 10.1053/j.ajkd.2003.09.023.

16. Kim YG, Suga S, Kang DH, et al. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int. 2000;58(6):2390–9. https://doi.org/10.1046/j.1523-1755.2000. 00427.x.

17. Suga A, Kim YG, Joly A, et al. Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney Int. 2001;60(4):1 297–308. https://doi.org/10.1046/j.1523-1755.2001.00935.x.

18. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1 129–36 doi: 10.1056%2FNEJMoa0707330.

19. Sison K, Eremina V, Baelde H, et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol. 2010;21(10):1 691–701 doi: 10.1681%2FNASN.2010030295.

20. El Karoui K, Vulliet V, Dion D, et al. Renal involvement in Castleman disease. Nephrol Dial Transplant. 2011;26(2):599–609. https://doi.org/10.1093/ndt/gfr427.

21. Usui T, Okada H, Itai H, et al. Endothelial cell injury in acute and chronic glomerular lesions in patients with IgA nephropathy. Hum Pathol. 2016;49: 135–44. https://doi.org/10.1016/j.humpath.2015.10.013.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.